Genetic Testing: Kidney Disorders
Customize your policy alerts
Sign up for all carolinabehavioralhealth policy alerts
Know when carolinabehavioralhealth releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage criteria for genetic and molecular testing used to establish or confirm inherited kidney disorders, evaluate APOL1-mediated kidney disease, and monitor kidney transplant rejection using donor-derived cell-free DNA.
Donor-derived cell-free DNA testing for kidney transplant rejection changed from non-covered to covered.
Comprehensive kidney disease panel criteria were expanded to include syndromic or multisystem features and the possibility of identifying a condition amenable to targeted treatment.
Polycystic kidney disease panel criteria removed intracranial aneurysm, poor corticomedullary differentiation, hepatobiliary abnormalities with progressive portal hypertension, and congenital hepatic fibrosis with portal hypertension.
Polycystic kidney disease targeted variant analysis was retired and testing for this condition is now reviewed under the General policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.